A Study of Obexelimab in Patients With Warm Autoimmune Hemolytic Anemia (SApHiAre)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT05786573 |
|
Recruitment Status :
Recruiting
First Posted : March 27, 2023
Last Update Posted : May 6, 2024
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Warm Autoimmune Hemolytic Anemia | Drug: Obexelimab Other: Placebo | Phase 3 |
This study consists of a 6-month open label Safety and Dose Confirmation Run-in Period (SRP), 6-month Randomized Control Period (RCP), and an additional 1-year open-label extension (OLE) period. To enter the Screening Period (Day -28 to Day -1) in the SRP or RCP, patients must have a clinical diagnosis of primary or secondary wAIHA due to an underlying autoimmune disorder, have failed at least 1 prior wAIHA treatment regimen, and have a Hgb level of ≥ 7 to < 10 g/dL with at least one sign or symptom of anemia. For the SRP only, patients with secondary wAIHA due to underlying lymphoproliferative disease may be eligible if they are receiving stable treatment.
All patients in the SRP or RCP are allowed to continue up to 2 failed wAIHA therapies throughout the 24-week study. On Day 1 of the SRP, patients receive obexelimab administered as subcutaneous (SC) injections. On Day 1 of the RCP, patients will be randomized in a ratio of 1:1 to receive either obexelimab or placebo administered as subcutaneous (SC) injections. Patients must return to the study site for the first 5 weeks and then every 2 weeks thereafter. Patients will undergo assessments for efficacy, safety, PK, PD, and immunogenicity during the 24-week SRP or RCP.
Following the 24-week SRP or RCP, patients will have the opportunity to receive obexelimab for up to 52 weeks in the Open Label Extension (OLE) Period.
Including screening and follow-up, the maximum duration of participation in this study for an individual patient is 81 weeks (i.e., 28-day screening, 24-week SRP or RCP, 52-week OLE, and an 8-week follow-up).
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 134 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
| Primary Purpose: | Treatment |
| Official Title: | A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With An Open Label Safety and Dose Confirmation Run-In Period, To Evaluate the Efficacy and Safety of Obexelimab in Patients With Warm Autoimmune Hemolytic Anemia (SApHiAre) |
| Actual Study Start Date : | September 25, 2023 |
| Estimated Primary Completion Date : | March 14, 2026 |
| Estimated Study Completion Date : | June 8, 2026 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Safety and Dose Confirmation Run-in Period (SRP): Obexelimab
Obexelimab will be administered as an SC injection for 24 weeks.
|
Drug: Obexelimab
Obexelimab is a monoclonal antibody that simultaneously binds CD19 and FcγRIIb, resulting in down regulation of B cell activity. |
|
Experimental: Randomized Control Period (RCP): Obexelimab
Obexelimab will be administered as an SC injection for 24 weeks.
|
Drug: Obexelimab
Obexelimab is a monoclonal antibody that simultaneously binds CD19 and FcγRIIb, resulting in down regulation of B cell activity. |
|
Placebo Comparator: Randomized Control Period (RCP): Placebo
Placebo will be administered as an SC injection for 24 weeks
|
Other: Placebo
Placebo |
- Safety and Dose Confirmation Run-in Period (SRP) [ Time Frame: 24 weeks ]Proportion of participants with hemoglobin (Hgb) ≥ 10 g/dL and ≥ 2 g/dL increase from Baseline with no use of blood transfusion or glucocorticoid (GC) rescue therapy.
- Randomized Control Period (RCP) [ Time Frame: 24 weeks ]Proportion of participants who achieve a durable Hgb response (defined as Hgb ≥ 10 g/dL and ≥ 2 g/dL increase from Baseline on at least 3 of 4 consecutive available visits), at the earliest on or after Week 12, with no use of blood transfusion or GC rescue therapy prior to attaining durable response through Week 24.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Males and females, ≥ 18 years of age
- Clinically diagnosed with wAIHA for at least 3 months and currently receiving treatment for wAIHA or have previously received treatment for wAIHA.
- Diagnosis of primary or secondary wAIHA documented by a positive direct antiglobulin test specific for anti-IgG or anti-IgA.
- Failed at least 1 prior wAIHA treatment regimen.
- At least one sign or symptom of anemia as assessed by the investigator at screening.
- Other inclusion criteria apply.
Exclusion Criteria:
- Have cold antibody AIHA, cold agglutinin syndrome, mixed type (i.e., warm, and cold) AIHA, or paroxysmal cold hemoglobinuria.
- Have any other associated cause of hereditary or acquired hemolytic anemia.
- For the RCP only, patients with secondary wAIHA not due to autoimmune disorders, including LPDs.
- Received a transfusion within 2 weeks prior to randomization.
- Use of B cell-depleting, B cell-targeted, or other biologic immunomodulatory agents within the 6 months prior to randomization.
- Received IV Ig or epoetin alfa within 6 weeks prior to randomization.
- Receiving more than 2 concomitant medications for the treatment of wAIHA.
- Other exclusion criteria apply.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05786573
| Contact: Patient and Medical Information | 833-269-4696 | clinicaltrialsinfo@zenasbio.com | |
| Contact: Zenas Patient Center | 213-459-2979 | studies@patientwing.com |
Show 47 study locations
| Responsible Party: | Zenas BioPharma (USA), LLC |
| ClinicalTrials.gov Identifier: | NCT05786573 |
| Other Study ID Numbers: |
ZB012-03-002 |
| First Posted: | March 27, 2023 Key Record Dates |
| Last Update Posted: | May 6, 2024 |
| Last Verified: | May 2024 |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
|
Warm Autoimmune Hemolytic Anemia wAIHA |
|
Anemia Anemia, Hemolytic Anemia, Hemolytic, Autoimmune Hemolysis |
Hematologic Diseases Pathologic Processes Autoimmune Diseases Immune System Diseases |